NCT02767557View on ClinicalTrials.gov

Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

January 26, 2017

Primary Completion Date

August 12, 2021

Study Completion Date

January 1, 2023

Conditions
Unresectable Pancreatic Carcinoma
Interventions
DRUG

Tocilizumab

Intravenous infusion

DRUG

Gemcitabine

Intravenous infusion

DRUG

nab-Paclitaxel

Intravenous infusion,

Trial Locations (2)

2730

Herlev & Gentofte University Hospital, Denmark, Herlev

0424

Department of Oncology, Oslo

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Herlev Hospital

OTHER